Download - Aphios amylon ncs_presentation_110113
Partnering for the future of human health™
a wholly owned subsidiary of Aphios Corporation
Developing a Novel Therapeutic, APH-1104
for
Alzheimer’s Disease and Cognitive Disorders
Dr. Trevor P. Castor President & CEO
3-E Gill Street, Woburn, MA 01801, USA
November, 2013
Partnering for the future of human health™
Alzheimer’s Disease (AD)
The average time from diagnosis to death is 4 to 8 years, although it may take 20 years or more for the disease to run its course
Significant neurological disorder that affects more than 4.5 million Americans and more than 10 million people worldwide
Total market of AD drugs in 2005 was over $2.7 billion; the market is expected to grow at a rate of 17.5% per year
The 4 FDA-approved drugs (e.g. Aricept, a cholin-esterase inhibitor) only treat the symptoms, not the underlying disease; currently, there is no cure for AD
Partnering for the future of human health™
Amyloid Plaque and Neurofibri l lary Tangle Formation in Alzheimer’s Disease
Partnering for the future of human health™
Novel Alzheimer’s Disease Therapeutics
Proteolytic processing of APP leading to extracellular A deposits involves the action of - and γ-secretases
Inhibitors of both - and γ-secretases have been evaluated as Aplaque-suppressing therapeutics in AD; while they are active in vitro, clinical trials have been largely unsuccessful
A recent Phase III clinical trial with Semagacestat, a γ-secretase inhibitor, by Eli Lilly was halted because of accelerated dementia
A recent Phase II clinical trial with a β-secretase inhibitor, LY2886721, also by Eli Lilly, was halted because of liver toxicity
There have been several Phase II and III clinical trial failures by Pfizer, AstraZeneca, Johnson & Johnson and Baxter
Partnering for the future of human health™
APH-1104 for Alzheimer’s Disease• A potent α-secretase modulator for
ameliorating Alzheimer's Disease patho-physiology and cognitive impairment with neuroprotection
• Exploratory Phase I/IIa clinical trial in the Bahamas (IV administration)
• Preclinical development of oral formulation (capsule and PNS nanotechnology)
• Next Steps – IND followed by Phase I/II clinical trials in the US
Partnering for the future of human health™
APH-1104 - Novel AD Therapeutic
APH-1104, an analog of APH-0703, up-regulates the production of -secretase which cleaves the amyloid precursor protein APP into a harmless soluble form sAPP- , which is non-neurotoxic and limits the formation of amyloid plaques
Both β-secretase and γ-secretase cleave APP to form an insoluble amyloid plaque (A ) that leads to tau entanglement
Thus, unlike current strategies which suppress β-secretase and γ-secretase to minimize A plaque formation, our strategy involves the activation of α-secretase leading to beneficial amyloid precursor processing and prevention of A buildup
Partnering for the future of human health™
Nanoencapsulated APH-0703 Effectively Activates -Secretase in Neuroblastoma Cells
α–secretase activity induced by APH-0703, Nano A, Nano B, Nano C and Nano D at 10-8M, 10-9M , 10-10M in SH-SY5Y neuroblastoma cells for 3h
APH-0703
Partnering for the future of human health™
Morris Maze TrialsA B
Latency to escape(Seconds to reach hidden platform)
Morris Maze trials (A) were conducted to measure the latency in seconds (B) of wild type and AD transgenic mice treated with vehicle alone and 5g APH-0703 to escape from mice swimming pool
Partnering for the future of human health™
APH-0703
Partnering for the future of human health™
Phase I / I Ia Exploratory Clinical Study of APH-0703, Nassau, Bahamas (n= 1)
• Patient - a 95 year old male with severe Alzheimer’s Disease
• Over 6-month period, MMSE score dropped from 20 to 15
• ADAS-Cog score increased from 29 to 38
• Patient also on several medications including Donepezil (Aricept 10 mg) and Memantine (10 mg) for memory loss
• After 2 i.v. cycles of APH-0703, patient very alert, remembers date, mind active, engaged in watching TV, aware of need to relieve himself, sleeping through the night
Partnering for the future of human health™
Summary
APH-0703, intravenously administered, shows preliminary efficacy in an Alzheimer’s Disease patient (n=1 study)
APH-0703 is a potent activator of -secretase which cleaves APP to form the soluble s-APP which is harmless, supports the formation of synapses, and can be removed in neuronal fluids
Nanoencapsulated APH-0703 significantly increases that activity of native APH-0703 in -secretase and PKC in vitro assays
APH-0703 continues to stimulate -secretase for at least 24h after it is removed from the cellular environment
Partnering for the future of human health™
Summary ( cont inued)
Oral APH-0703 in oil and nanoparticle formulations significantly improve learning and memory retention in the transgenic mouse model, APP/PS1, of Alzheimer’s disease
These effects are seen within 2 weeks of administration, earlier than in any previous study
Retention studies indicate that memory improvements persist for at least 3 weeks following drug washout
APH-1104, a more potent analog of APH-0703, formulations represent a highly effective modality for treating Alzheimer’s Disease
Partnering for the future of human health™
Next Steps
Establish cGMP for API and FDP at the pilot-scale level (ongoing)
Establish a Drug Master File, design IND enabling preclinical studies and Phase I/IIa clinical trials, and draft IND package (ongoing)
Conduct FDA-necessary IND-enabling preclinical in vivo studies, including toxicology, efficacy and pharmacology, under GLP
Perform stability testing of API and FDP under GLP
File IND for conducting Phase I/IIa clinical trial of oral APH-1104
Conduct Phase IIb clinical trials
Partnering for the future of human health™
Contact Information
• Office Phone: 001 (781) 932-6933
• Cell Phone: 001 (781) 858-7520
• Office Fax: 001 (781) 932-6865
• E-mail: [email protected]
• Website: www.aphios.com
• Mailing Address: 3-E Gill St. Woburn,
MA 01801 USADr. Trevor P. Castor, CEO